Calreticulin mutations are exceedingly rare in patients with myelodysplastic syndromes with myelofibrosis

Dear Editor, Myelodysplastic syndromes (MDSs) with myelofibrosis (MF) account for 15 % of MDS cases and typically show a worse overall survival and an increased risk of transformation into acute myeloid leukemia than MDS without fibrosis [1]. Primary myelofibrosis (PMF) is classified in the group of the myeloproliferative neoplasms (MPNs) and commonly… CONTINUE READING